Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 14 July, 2011 and appeared in  Cardiovascular HealthBlood Glucose ControlType 2 DiabetesAging and Diabetes SlidesIssue 582

Targeting Postprandial Versus Fasting/Premeal Glycemia More Effective in Reducing Cardiovascular Risk

Older type 2's improve cardiovascular risks when using insulin and targeting postprandial versus fasting glycemia....

Advertisement

The trial was done to identify the Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (HEART2D) trial subgroups with treatment difference.  

In 1,115 type 2 diabetic patients who had suffered from an acute myocardial infarction (AMI), the HEART2D trial compared two insulin strategies targeting postprandial or fasting/premeal glycemia on time until first cardiovascular event (cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or hospitalization for acute coronary syndrome). The HEART2D trial ended prematurely for futility. We used the classification and regression tree (CART) to identify baseline subgroups with potential treatment differences.

The results showed that theestimated the age of >65.7 years to best predict the difference in time to first event. In the subgroup aged >65.7 years (prandial, n = 189; basal, n = 210), prandial patients had a significantly longer time to first event and a lower proportion experienced a first event (n = 56 [29.6%] vs. n = 85 [40.5%]; hazard ratio 0.69 [95% CI 0.49–0.96]; P = 0.029), despite similar A1C levels.

From the results it was concluded that older type 2 diabetic AMI survivors may have a lower risk for a subsequent cardiovascular event with insulin targeting postprandial versus fasting/premeal glycemia.

Diabetes Care, July 2011

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 14 July, 2011 and appeared in  Cardiovascular HealthBlood Glucose ControlType 2 DiabetesAging and Diabetes SlidesIssue 582

Past five issues: Special Edition - Getting Patients on Track | Diabetes Clinical Mastery Series Issue 84 | Issue 625 | Diabetes Clinical Mastery Series Issue 83 | Issue 624 |

 
Diabetes In Control Advertisers
 
 
Cast Your Vote
Generics are usually just as safe and effective as the corresponding name-brand product.

Navigate Diabetes In Control
Search Articles On Diabetes In Control